# A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL

> **NCT04532268** · EARLY_PHASE1 · RECRUITING · sponsor: **Zhejiang University** · enrollment: 72 (estimated)

## Conditions studied

- Acute Lymphoblastic Leukemia
- Non-hodgkin Lymphoma,B Cell

## Interventions

- **DRUG:** Humanized CD19 CAR-T cells

## Key facts

- **NCT ID:** NCT04532268
- **Lead sponsor:** Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-08-23
- **Primary completion:** 2023-08-23
- **Final completion:** 2026-08-23
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2020-08-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04532268

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04532268, "A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04532268. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*